Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: INVEGA SUSTENNA

« Back to Dashboard
Invega Sustenna is a drug marketed by Janssen Pharms and is included in one NDA. It is available from one supplier. There are two patents protecting this drug.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the paliperidone palmitate profile page.

Summary for Tradename: INVEGA SUSTENNA

Patents:2
Applicants:1
NDAs:1
Suppliers: see list1
2013 Sales:$779,834,000

Pharmacology for Tradename: INVEGA SUSTENNA

Clinical Trials for: INVEGA SUSTENNA

Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism
Status: Withdrawn Condition: Bipolar Disorder

A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate
Status: Completed Condition: Schizophrenia

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia
Status: Recruiting Condition: Schizophrenia (Recent-onset)

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
Status: Not yet recruiting Condition: Schizophrenia; Psychotic Disorders

A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
Status: Completed Condition: Schizophrenia

A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia
Status: Completed Condition: Schizophrenia

The Effect of Paliperidone Palmitate in Schizophrenia
Status: Recruiting Condition: Schizophrenia

Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)
Status: Completed Condition: Schizophrenia

A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia
Status: Completed Condition: Schizophrenia

A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia
Status: Completed Condition: Schizophrenia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-001Jul 31, 2009RXNo6,555,544*PED<disabled>Y<disabled>
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-005Jul 31, 2009RXNo6,077,843*PED<disabled>Y<disabled>
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-002Jul 31, 2009RXNo<disabled><disabled>
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-001Jul 31, 2009RXNo<disabled><disabled>
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-003Jul 31, 2009RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc